Investor Relations

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.

Lipocine Reports Topline Results From Phase 2 Proof-Of-Concept Study of LPCN 1148 in Liver Cirrhosis

Thursday, July 27, 2023

8:30am EDT

Innovating beyond boundaries for patients

Krista Fogarty phone: (801) 994-7383 email: kf@lipocine.com